Resilient Biotics is utilizing big data analytics to design microbiome-based therapeutics and advanced screening methods for prevention and precision treatment of deadly infectious diseases. Our goal is to provide more effective treatment strategies while reducing dependency on antibiotics.
Resilient Biotics utilizes deep sequencing and a machine learning-based computational platform to characterize host genotypes, commensal microbial communities, and pathogen strain variants for unprecedented microbiome resolution. Our analytics rapidly identify important genetic elements and key microbial strains that influence states of health and disease.
We sift through terabases of data to uncover unique signatures associated with disease occurrence. Our comprehensive profiling methods characterize infectious microorganisms across the entire genome in order to identify important pathogenic strains and virulence-causing genes. Our in-house heuristic search methods can rapidly pinpoint diagnostic biomarkers for pathogen identification and risk prediction. Importantly, accurate disease profiling enables the use of targeted therapeutic and disease management strategies.
Healthy microbiome communities promote host health and resist invasion by infectious pathogens. However, a robust and diverse microbial community can have thousands to hundreds of thousands of microbial strains. Our task is to parse through each of these strains to identify those responsible for positive health outcomes and pathogen resistance. Using pattern recognition and network algorithms, we identify specific microbial strains and community structures that are beneficial to the host and prevent pathogen colonization.
Resilient Biotics is actively developing live biotherapeutics to address infectious and inflammatory diseases of the respiratory tract.